Physician profile
Laura Morris
NPI 1629092853
$2,488.28
in general payments reported to CMS, 2019-2025
29 companies · $735 in 2025
The $735 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $364 · 2023: $459 · 2024: $555 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $274.29 | 2021-2025 | Watchman Flx, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $238.05 | 2022-2025 | |
| Amgen INC. | $157.82 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $139.27 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $128.22 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.99 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $124.88 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Cvrx, INC. | $114.41 | 2022-2025 | Barostim Neo System |
| Pfizer INC. | $111.24 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $98.62 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $97.98 | 2025 | |
| Atricure, INC. | $96.79 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $94.65 | 2022-2024 | Camzyos, Eliquis |
| Angiodynamics, INC. | $83.45 | 2021 | |
| Chiesi USA, INC. | $77.99 | 2024-2025 | Juxtapid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $70.09 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $67.51 | 2021-2023 | Farxiga |
| Inspire Medical Systems, INC. | $57.91 | 2025 | Inspire |
| Medtronic, INC. | $54.90 | 2023-2024 | Linq II, Reveal Linq |
| Esperion Therapeutics, INC. | $53.89 | 2021-2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $43.14 | 2021 | |
| Veryan Medical Incorporated | $39.73 | 2021 | |
| Impulse Dynamics (USA) INC. | $29.10 | 2025 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $27.18 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $19.53 | 2022 | |
| Amarin Pharma, INC. | $17.30 | 2021 | |
| Abiomed | $16.72 | 2024 | Impella |
| Kestra Medical Technology Services, INC. | $13.22 | 2023 | Assure Wcd |
| Cardiva Medical, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.